Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.

Status: Terminated

Protocol number: ML20910

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, open label study to evaluate the effect of Tamiflu on viral shedding and on serum and cytoplasmic inflammatory cytokine concentrations in patients with laboratory-confirmed influenza

Brief summary: This study will evaluate the efficacy and safety of Tamiflu in patients with clinically-diagnosed influenza occurring during an influenza outbreak within the community. Patients will be randomized to receive Tamiflu 75mg bid orally plus support therapy (NSAIDs and antibiotics) or support therapy alone. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals. Target sample size is 46.

Study phase: IV

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Influenza

Intervention type: Drug

Intervention name: oseltamivir [Tamiflu]

Primary outcome: 1. Viral shedding; serum and intracellular concentrations of inflammatory cytokines (INFgamma, TNFalpha, IL-6, IL-12).

Key secondary outcomes: 1. Efficacy: Duration of illness, health and functional status, extent and severity of symptoms, incidence of resistant viruses. Safety: AEs.

Inclusion criteria:

  • adult patients, 18-64 years of age;
  • ambulatory;
  • influenza-like illness;
  • positive rapid assay for detection of influenza antigen.

Exclusion criteria:

  • presentation >36h after onset of symptoms;
  • influenza-like symptoms outside an outbreak based on local surveillance activities;
  • influenza vaccination between November 2006 and January 2007;
  • receipt of antiviral therapy, systemic steroids or immunosuppressants within 2 weeks prior to study day 1.

Gender: Males or Females

Age limits: Min: 18 Years Max: 64 Years

Accepts healthy volunteers: No

Trial registration date: 02/16/2007

Date last updated: 11/21/2008


Link to trial result

This trial was conducted at the following locations:

Italy

  • Genova

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply